Drug Trial Radar · NCT00222573
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
Last checked: Nov 19, 2026Latest source record: May 5, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46,000
Actual
Start
Jul 1999
Primary completion
Not stated
Study completion Feb 2005
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi; AstraZeneca
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible provided they were thought to have ST elevation or other ischaemic ECG abnormality with no clear indication for, or contraindication to, trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death. (Patients were also randomised separately in a 2 X 2 factorial design between metoprolol versus placebo.) The two main study endpoints are death and the composite outcome of death, non-fatal reinfarction or stroke during the scheduled treatment period in hospital.
Conditions
- Acute Myocardial Infarction
Interventions
clopidogrel and metoprololDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death and the composite outcome of death, non-fatal reinfarction or stroke
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Institute of Cadiovascular diseases, Fuwai hospital, Chinese academy of medical sciences
Beijing, China
Clinical Trial Service Unit and Epidemiological Studies Unit
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.